Literature DB >> 1477076

Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives.

H Futami1, L Eader, T T Back, E Gruys, H A Young, R H Wiltrout, B C Baguley.   

Abstract

Derivatives of xanthenone-4-acetic acid (XAA) have been found to have similar activity to flavone-8-acetic acid against transplantable solid tumors. Some of these compounds were compared to flavone acetic acid (FAA) in their ability to induce cytokines as well as to mediate antitumor effects against murine renal cancer (Renca) and a mouse colon cancer (MCA-38). 5-Methyl-XAA and 5-chloro-XAA proved to be more potent than FAA on a mg/kg basis for induction of the genes for IFN alpha, IFN gamma, and TNF alpha, and for IFN and TNF activities in the sera of treated mice. These effects were sharply dose dependent. On the other hand, 7-methyl-XAA, which has no antitumor activity, did not induce these genes. In addition, 5-methyl-XAA and 5-chloro-XAA but not 7-methyl-XAA synergized with recombinant human interleukin-2 (rhIL-2) for the treatment of Renca and MCA-38. Doses of the active derivatives that failed to induce cytokines also exhibited no therapeutic synergy with rhIL-2. These results suggest that at least some of the antitumor effects of these XAA derivatives are related to their ability to induce cytokines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1477076     DOI: 10.1097/00002371-199211000-00005

Source DB:  PubMed          Journal:  J Immunother (1991)        ISSN: 1053-8550


  6 in total

Review 1.  5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Authors:  Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

2.  Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.

Authors:  L L Thomsen; B C Baguley; W R Wilson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  M Philpott; B C Baguley; L M Ching
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.

Authors:  L M Ching; W R Joseph; L Zhuang; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  E Moilanen; L L Thomsen; D W Miles; D W Happerfield; R G Knowles; S Moncada
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

6.  Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.

Authors:  L M Ching; W L Browne; R Tchernegovski; T Gregory; B C Baguley; B D Palmer
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.